Wellnex Life Ltd · ASX:WNX
Wellnex Life — Investor Presentation (September 2022)
17 slides from Wellnex Life's investor presentation, Sep 14, 2022
Slide 1: ASX Announcement: Investor Presentation
ASX Announcement 14 September 2022 Investor Presentation For personal use only Wellnex Life Limited (ASX: WNX), a brand and distribution company of customer-focused health and wellness products, is pleased to announce that they will be holding a live investor briefing on Thursday 15 September at 11a
Slide 2: Wellnex Life Investor Presentation September 2022
For personal use only Wellnex Life (ASX: WNX) Investor Presentation September 2022
Slide 3: Disclaimer
2 Wellnex Life (ASX: WNX) Investor Presentation | September 2022 Disclaimer For personal use only The material in this presentation has been prepared by Wellnex Life Limited ACN 150 759 Historical information in this presentation relating to Wellnex is information that has 363 (Wellnex or the Compan
Slide 4: Who we are
3 Wellnex Life (ASX: WNX) Investor Presentation | September 2022 Who we are For personal use only Wellnex Life is a brand and product innovator operating in the fast-growing health and wellness market. Wellnex aiming to be one of the first companies to launch an over-the-counter Schedule 3 medicinal
Slide 5: A huge untapped market with evolving needs
4 Wellnex Life (ASX: WNX) Investor Presentation | September 2022 A huge untapped For personal use only market with Consistent growth in Global CBD market evolving needs target segments • Consumer desire for product innovation CAGR 21.7% $10.7B* • Health and wellness a leading priority in consumer sp
Slide 6: Our key competencies
5 Wellnex Life (ASX: WNX) Investor Presentation | September 2022 Our key competencies For personal use only 1. 2. 3. Identify consumer Create brands and Retail trade activation – trends. products capturing first or fast into retailers’ these trends. stores. Regulatory Manufacturing Distribution know
Slide 7: Wellnex brands and contract manufacturing
6 Wellnex Life (ASX: WNX) Investor Presentation | September 2022 Wellnex brands Contract manufacturing For personal use only * * Wagner Liquigesic is a WNX trademark
Slide 8: Established distribution networks
7 Wellnex Life (ASX: WNX) Investor Presentation | September 2022 Established distribution networks For personal use only Established Key pharmacy Key pharmacy Blue chip Australian wholesalers retailers supermarkets national coverage of over 90% of the health and wellness market
Slide 9: Building sales momentum
8 Wellnex Life (ASX: WNX) Investor Presentation | September 2022 Building sales momentum For personal use only Sales up 192% in 8 months to August 2022 Sales up 132% in 8 months to August 2022 Sales up 61% in 6 months to July 2022
Slide 10: Next major opportunity: S3 cannabis
9 Wellnex Life (ASX: WNX) Investor Presentation | September 2022 Next major opportunity: For personal use only S3 cannabis Rising awareness of health benefits of cannabidiol (CBD) and its effectiveness in pain management & various other treatments is propelling industry growth. Global CBD market USD
Slide 11: Why Wellnex can win
10 Wellnex Life (ASX: WNX) Investor Presentation | September 2022 Why Wellnex can win For personal use only Wellnex will approach the S3 market opportunity utilising its tried and tested go-to-market approach. Wellnex has formed a strategic partnership with OneLife Botanicals. Wellnex will have acce
Slide 12: Case study: Partnership deal – Wagner Liquigesic (process)
11 Wellnex Life (ASX: WNX) Investor Presentation | September 2022 Case study For personal use only Partnership deal – Wagner Liquigesic The process: Consumer research • Consumers want a faster form of pain relief • Consumers prepared to pay a premium for fast pain relief Product development • Techni
Slide 13: Case study: Partnership deal – Wagner Liquigesic (outcome)
12 Wellnex Life (ASX: WNX) Investor Presentation | September 2022 Case study For personal use only Partnership deal – Wagner Liquigesic The outcome: First TGA-approved soft gel liquid paracetamol Ranged commenced October 2021 in c. 500 stores across Chemist Warehouse network Sales up 61% in 6 months
Slide 14: Revenue
13 Wellnex Life (ASX: WNX) Investor Presentation | September 2022 Revenue Revenue For personal use only $35 MILLIONS Increasing revenue of our own brands will increase $30 29 overall profit margin. $25 Key to moving towards $20 18.3 18.6 positive EBITDA. 15.4 $15 12.3 $10 6.7 $5 $0 FY18 FY19 FY20 FY
Slide 15: Investment thesis
14 Wellnex Life (ASX: WNX) Investor Presentation | September 2022 Investment thesis Secondary services For personal use only Our core competencies Our target markets Our strategy • Identify category trends • Fast growing health and wellness • Leverage all of our key retailer and manufacturer partner
Slide 16: Pipeline: upcoming events in FY23
15 Wellnex Life (ASX: WNX) Investor Presentation | September 2022 Pipeline For personal use only Numerous upcoming value inflection points and material news flow Upcoming events in FY23 Approval of acquisition of Mr. Bright, teeth whitening brand Launch of Organic A2 infant formula, Ocean Road Dairi
Slide 17: Thank you
16 Wellnex Life (ASX: WNX) Investor Presentation | September 2022 For personal use only Thank you. George Karafotias Chief Executive Officer Investor Relations T 1300 805 795 E ir@reachmarkets.com.au
Wellnex Life — Investor Presentation (September 2022) on 6ix